ANG Lifesciences India Ltd Management Discussions

Annexure-8

GLOBAL PHARMACEUTICAL INDUSTRY

The pharmaceutical industry is critical to patient care and community development as it not only provides numerous life-saving treatments but also generates employment and contributes to the world economy. Amidst the challenging global landscape of inflation, pandemic, and escalating geopolitical tensions in 2023, international health systems exhibited remarkable resilience. The industry witnessed a continued focus on adopting novel therapies and a sustained increase in overall usage.

On 5 May 2023, the World Health Organization (WHO) declared the end of the COVID-19 public health emergency. This changed the dynamics of the pharmaceutical world, shifting it back to the prevention and treatment of other communicable and non-communicable diseases.

INDIAN PHARMACEUTICAL INDUSTRY

The Indian pharmaceutical sector is the third largest supplier by volume in the world. With 20% of the global supply share, India is also known as the Pharmacy of the World. To get a sense of its manufacturing abilities, India has the highest number of US-FDA compliant Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing as well as a highly skilled resource pool.

There has been a notable shift in the Indian consumer mindset, reflected in the growing demand for vitamins, minerals, and supplements (VMS). According to IMARC, the Indian pharmaceutical market is expected to reach to US$ 163.1 billion by 2032, at 12.3% CAGR. The growing incidences of diseases, rising healthcare needs, favorable government initiatives prioritizing healthcare, development of healthcare infrastructure, and improving health consciousness will provide a boost to future market growth.

OVERVIEW OF THE COMPANY

With the strong commitment to serve to the mankind predominantly, with an objective to provides top Quality & cost effective Products, ANG-Group is always at the forefront in the Institutional supplies at domestic market as well as its presence at Export market & has acquired always a prominent place & pivotal role amongst the Indian Pharmaceuticals Industries.

ANG Group is a WHO-GMP certified groups of Pharmaceuticals Companies, having its presence even at Global road map also, currently all units are situated at Industrial township of Baddi, Himachal Pradesh India. ANG Group of Companies have been commissioned with an "State of an Art" manufacturing facilities equipped with Ultra- modem manufacturing equipment facilities as per WHO-GMP standards and entire Group is mainly engaged in the core manufacturing and marketing of wide range of fine-grade finished pharmaceuticals formulations especially Non Beta-Lactum, Beta Lactum, Cephalosporin & Carbapenem with a range of products in the available dosage forms of Dry Powder injection , Tablets , Hard Gelatin Capsules, Liquid syrup, Liquid Injection- Ampoule/Vials & PFS(pre filled syringes).

OPPORTUNITIES, RISKS, CONCERNS & THREATS

In the financial year 2023-24, global economy witnessed slowdown in growth impacted by the Ukraine - Russia conflict, persistently high inflation levels across all major economies in the world. Despite uncertainties, particularly ones engendering from economic and geopolitical circumstances, the industry is expected to regain its growth rates by 2024-25. The global pharmaceutical market is projected to grow at a CAGR of 3-6% between 2023 and 2027.

The Company does not perceive any risks or concerns other than those that are common to the industry such as regulatory risks, exchange risk, cyber risks and other commercial and business-related risks.

AMG Lifesciences India Limited will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization.

FINANCIAL PERFORMANCE

(In Rupees Lacs)

The details of changes in key financial ratios are explained in the table below:-

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY

The Companys defined organizational structure, documented policy guidelines and adequate internal controls ensure efficiency of operations, compliance with internal policies, applicable laws and regulations, protection of resources and assets and accurate reporting of financial transactions. The Company continuously upgrades these systems in lire with best available practices.

The control systems are reviewed by the management regularly. The same are also reviewed by the Statutory Auditors and Internal Auditors from time to time. The Company has also adopted various policies and procedures to safeguard the interest of the Company. These policies and procedures are reviewed from time to time. There has also been proper reporting mechanism implemented in the organization for reporting any deviation from the policies and procedures. Compliance audit is also conducted from time to time by external agencies on various areas of operations.

INVESTOR RELATIONS AND ENGAGEMENT:

Investor Relations (IR) is playing an increasingly important role in todays volatile world in enabling companies to manage investor expectations. The objectives of Companys investor relations activities are to boost confidence and develop a long-term relationship of trust with stakeholders including Shareholders.

Investors & Analysts, through true and fair disclosure of information. To pursue these objectives at all times, our Company continuously discloses necessary information.

HUMAN RESOURCES VISnA-VIS INDUSTRIAL RELATIONS

Human resources continue to be one of the critical assets of the organization. The company recognizes the importance of human value and ensures that proper encouragement both moral and financial is extended to employees to motivate them. The human resources received commensurate attention during the year considering the growth of the organization and the need arising there from. Attracting relevant talent remains the Companys key focus. It always pays special attention to training, welfare and safety of its people, strengthening human capabilities.

CAUTIONARY STATEMENT

The statements in the "Management Discussion and Analysis Report" section describe an optimistic approach of the management regarding the Companys visions strategies objectives projections estimates expectations and predictions. These may be "forward looking statements" within the meaning of legal framework. However, the annual performance can differ significantly from those expressed or implied depending upon the market conditions economic and climatic conditions Government policies and other incidental factors.

For ANG Lifesciences India Limited